CLEMEDI
Clemedi develops in vitro diagnostic tests for infectious diseases, by uniting two novel technologies โ Next-generation Sequencing and Machine learning. They will contribute to limiting deaths caused by antibiotic resistant bacteria, projected to reach 10 million annually in 2050! Our diagnostic tests support doctorsโ decision-making by enabling him or her to give a timely and personalized antibiotic therapy. Ultimately, patients suffering from infectious diseases will benefit with their product.
CLEMEDI
Industry:
Biotechnology Health Care
Founded:
2018-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.clemedi.com
Total Employee:
1+
Status:
Active
Contact:
+41 77 98 040 61
Email Addresses:
[email protected]
Total Funding:
30.71 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome
Current Employees Featured
Founder
Investors List
MassChallenge
MassChallenge investment in Non Equity Assistance - Clemedi
Venture Kick
Venture Kick investment in Grant - Clemedi
Venture Kick
Venture Kick investment in Grant - Clemedi
Official Site Inspections
http://www.clemedi.com
- Host name: boethin.uberspace.de
- IP address: 185.26.156.96
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin

More informations about "Clemedi"
Clemedi โ Ending antibiotic misuse
Clemedi is a startup company developing an innovative best-in-class platform to diagnose infectious diseases without bacterial culture. We are currently raising CHF 4 million to finance โฆSee details»
Clemedi - Crunchbase Company Profile & Funding
Clemedi develops in vitro diagnostic tests for infectious diseases, by uniting two novel technologies โ Next-generation Sequencing and Machine learning. They will contribute to โฆSee details»
About - Clemedi
To address this, Clemedi is developing in vitro molecular diagnostic test kits to diagnose drug resistant infections directly from patient samples, within 24 hours. Our tests combine molecular โฆSee details»
Our Team โ Clemedi
Dr. Houda Youssefi, Director of sales North Africa. Board of Directors. Prof. Thorsten BuchSee details»
Clemedi AG - Swiss Biotech
Clemedi combines DNA sequencing and artificial intelligence to recommend the optimal antibiotic therapy for every patient. Our products help with managing infectious diseases such as tuberculosis, sexually transmitted infections or โฆSee details»
Clemedi AG Company Profile | Schlieren, ZÜRICH, Switzerland ...
Find company research, competitor information, contact details & financial data for Clemedi AG of Schlieren, ZÜRICH. Get the latest business insights from Dun & Bradstreet.See details»
Clemedi | LinkedIn
Clemedi | 488 abonnés sur LinkedIn. Ending antibiotic misuse | Ending Antibiotic Misuse. Clemedi is a paradigm shift Clemedi provides complete information to clinicians when most needed: โฆSee details»
Clemedi 2025 Company Profile: Valuation, Funding & Investors
Clemedi General Information Description. Developer of a disease management platform designed to render comprehensive information for targeted therapy. The company's platform combines โฆSee details»
clemedi | VentureRadar
Similar Companies: Susan R. Windham-Bannister Unknown n/a Dr. Windham-Bannister is an experienced CEO who served as the founding President and CEO of the Massachusetts Life โฆSee details»
Prajwal Prajwal Profile: Contact Information & Network - PitchBook
Dr. Prajwal Prajwal is a Co-Founder & serves as Chief Scientific Officer & Board Member at Clemedi. Contact Information. Primary Position. Co-Founder, CSO & Board Member, Clemedi. โฆSee details»
Clemedi on LinkedIn: #clemedi #boardmember #diversity โฆ
Clemediโs Post Clemedi 486 followers 1y Report this post We are delighted to announce the appointment of Dr. Manuela Schneider-Höfferer to our Board of Directors. ...See details»
Clemedi schliesst Lizenzvereinbarung zum Nachweis latenter โฆ
Dec 19, 2022 Clemedi beabsichtigt, seine Tuberkulose-Produktlinie auf die Diagnose latenter Tuberkulose zu erweitern. Dies erfordert die Fähigkeit, Mycobacterium tuberculosi-DNA aus โฆSee details»
Press Release โ Clemedi
Dec 16, 2022 Clemedi aims to extend its tuberculosis product line to cover latent tuberculosis. ... As the technology transfer organization of the Max Planck Society, Max Planck Innovation is โฆSee details»
Clemedi - Today, Clemedi has participated in the Swiss... - Facebook
Today, Clemedi has participated in the Swiss Diagnostics Start-Up Day 2018 and won 2nd place in the Swissbiolabs Award!See details»
Clemedi medical device development โ a pipeline landscape
Clemedi and its subsidiaries are currently working on the development of 6 products that fall under the In Vitro Diagnostics markets. GlobalDataโs report Clemedi Medical Device โฆSee details»
List of Horizon 2020 projects coordinated by "CLEMEDI AG"
Horizon2020 projects coordinated by "CLEMEDI AG" # project acronym year total cost totalcontribution ; 1: TUBERCULINI A novel in-vitro diagnostic test for drug-resistant โฆSee details»
ClearMed
WHO WE ARE. We are healthcare communication experts with over two decades of strategic marketing agency experience. We are a minority and women-owned company.See details»
Home Storage & Organization - Walmart.com
Shop for all your storage & organization needs at Walmart.com: shelving, closets, laundry, and office storage. Free Shipping over $35 and free pickup.See details»
Clemedi Update Q4 2021 โ Clemedi
Clemedi conducted interviews with key-opinion leaders to validate the product-market fit of current and future products. Also, Niko attended three (virtual) conferences, South Summit, Wolf โฆSee details»
10 Organizational Issues (With Causes and Solutions)
Sep 9, 2024 To promote innovation and creativity in the organization, you can encourage employees to think differently, discuss new ideas, implement fresh strategies, and experiment. โฆSee details»